Key result
Seven days of treatment with rofecoxib or naproxen did not significantly change acetylcholine-mediated increases in forearm blood flow in healthy volunteers (P=0.58 and P=0.27, respectively).
Why the study?
Does rofecoxib impair endothelial vasodilator function compared to naproxen in healthy volunteers?
RCT (n=35)
randomized
Does rofecoxib impair endothelial vasodilator function compared to naproxen in healthy volunteers?
p-value: P=0.58
Short-term treatment with the COX-2 inhibitor rofecoxib does not impair endothelial vasodilator function in healthy volunteers.
No takes yet. Share an insight, caveat, or question.
Short-term rofecoxib does not impair endothelial function in healthy volunteers; extends RCT safety data but leaves effects in patients or with chronic use open.
Verma et al. (2001) conducted an RCT in Healthy volunteers (n=35). Rofecoxib vs. Naproxen (750 mg/d) was evaluated on Changes in forearm blood flow in response to the endothelium-dependent vasodilator acetylcholine (p=P=0.58). Seven days of treatment with rofecoxib or naproxen did not significantly change acetylcholine-mediated increases in forearm blood flow in healthy volunteers (P=0.58 and P=0.27, respectively).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: